Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H11NO2.ClH |
| Molecular Weight | 189.639 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCC(O)C1=CC=CC(O)=C1
InChI
InChIKey=OWMFSWZUAWKDRR-UHFFFAOYSA-N
InChI=1S/C8H11NO2.ClH/c9-5-8(11)6-2-1-3-7(10)4-6;/h1-4,8,10-11H,5,9H2;1H
DescriptionSources: http://www.ndrugs.com/?s=norfenefrineCurator's Comment: Description was created based on several sources, including http://www.kegg.jp/entry/D08286 and http://www.ncbi.nlm.nih.gov/pubmed/6351455
Sources: http://www.ndrugs.com/?s=norfenefrine
Curator's Comment: Description was created based on several sources, including http://www.kegg.jp/entry/D08286 and http://www.ncbi.nlm.nih.gov/pubmed/6351455
Norfenefrine or meta-octopamine, also known as 3,β-dihydroxyphenethylamine, is an adrenergic agent used as a sympathomimetic drug which is marketed in Europe, Japan, and Mexico. Along with its structural isomer p-octopamine and the tyramines, norfenefrine is a naturally occurring, endogenous trace amine and plays a role as a minor neurotransmitter in the brain. Norfenefrine controls blood pressure in acute hypotensive states eg pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesth, MI, septicemia, blood transfusion and drug reactions. Adjunct in treatment of cardiac arrest and hypotension.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094251 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08286 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Nevadral Retard Approved UseIndications: hypotension |
Doses
| Dose | Population | Adverse events |
|---|---|---|
30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (4.3%) Sources: |
90 mg single, oral Studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 4.3% Disc. AE |
30 mg 3 times / day multiple, oral Studied dose Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A multichannel electrophoresis microchip platform for rapid chiral selector screening. | 2008-05 |
|
| A new copper(I)-tetrahydrosalen-catalyzed asymmetric Henry reaction and its extension to the synthesis of (S)-norphenylephrine. | 2007 |
|
| Chiral separations on multichannel microfluidic chips. | 2005-12 |
|
| Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model. | 2005 |
|
| [Efficacy and safety of a herbal drug containing hawthorn berries and D-camphor in hypotension and orthostatic circulatory disorders/results of a retrospective epidemiologic cohort study]. | 2005 |
|
| Heat shock protein 72 and apoptosis indicate cardiac decompensation during early multiple organ failure in sheep. | 2004-07 |
|
| Sympathetic regulation of glucose uptake by the alpha1-adrenoceptor in human obesity. | 2004-04 |
|
| Early multiple organ failure after recurrent endotoxemia in the presence of vasoconstrictor-masked hypovolemia. | 2003-03 |
|
| In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects. | 2002-04 |
|
| Effects of norepinephrine on the oxidative pentose phosphate pathway in the rat heart. | 1992-08 |
|
| Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. | 1989-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6150569
Curator's Comment: Can also be administered inramuscularly
http://www.ncbi.nlm.nih.gov/pubmed/7197979
For the treatment of female stress incontinence 60 mg were given in slow-release tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6147146
At 0.1 and 1 umol/l, norfenefrine caused contractions of the rabbit pulmonary artery strips
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1046710
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL358040
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
20907
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
236468
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
1473206
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
15308-34-6
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
SUPERSEDED | |||
|
4779-94-6
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
C81364
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
297582
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
C005310
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
100733
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
m8058
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000085722
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
239-351-1
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
ALTERNATIVE | |||
|
1FCN9TAU6R
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
SUB03459MIG
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY | |||
|
225-323-6
Created by
admin on Mon Mar 31 17:53:34 GMT 2025 , Edited by admin on Mon Mar 31 17:53:34 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD